Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

HBDC program," said John Bishop, Cepheid's Chief Executive Officer.  "Despite these distractions, we were able to grow our clinical test revenue by 32%, including 25% growth in our commercial business."

Continued Bishop, "We are proud of our commitment to innovation, and our investment in R&D continues to be among the most aggressive in the industry.  As we move into 2013 and beyond, Cepheid is entering a pivotal period of Xpert test menu expansion with a number of high volume, high value tests that substantially extend our opportunities in new and existing markets.  We fully expect this product cycle to drive both market expansion and menu consolidation within accounts thereby benefiting continued, industry-leading revenue growth and improving profitability."

Operational Overview

  • Fourth quarter of 2012 Clinical sales of $82.2 million grew 19% from $68.9 million in the fourth quarter of 2011, and total fourth quarter of 2012 product sales of $89.7 million grew 17% from the same quarter a year ago.  For the year ended December 31, 2012, total Clinical sales of $286.3 million grew 21% from $236.0 million reported for 2011. 
  • By industry, product sales were, in millions:
  • Three Months Ended December 31,Full Year Ended December 31,20122011Change20122011ChangeClinical Systems

    $  13.4$  19.9-33%$
    52.8$
    58.6-10%Clinical Reagents

    68.849.040%233.5177.432%Total Clinical 82.268.919%286.3236.021%Non-Clinical

    7.58.0-6%35.229.519%Total Product Sales$  89.7$  76.917%$  321.5$  265.521%


  • By geography, product sales were, in millions:
  • Three Months Ended December 31,Full Year Ended December 31,20122011Change20122011ChangeNorth AmericaClinical

    $  54.4$  46.417%$  190.0$  167.913%Other

    6.07.2-17%29.025.016%Total North America60.453.613%219.0192.914%InternationalClinical

    27.822.524%96.368.
    '/>"/>

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Cepheid to Webcast Upcoming Financial Presentations
    2. Cepheid Announces Executive Vice President Emerging Markets
    3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    10. Luminex Corporation Reports First Quarter 2012 Results
    11. Hospira Reports First-Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), ... focused on commercialization of its non-invasive Monarch ... and neuropsychiatric disorders, today announced that enrollment has begun ... nerve stimulation (eTNS) as adjunctive therapy for the treatment ... being conducted at the Olive View-UCLA Medical Center in ...
    (Date:7/22/2014)... York , July 22, 2014 ... Partnerschaft für umfassenden Schutz von Pharmazeuten ... Österreich    Equashield ( ... Transfersystemen (Closed System Transfer Devices, CSTDs) für gefährliche ... einen Vertriebshändler und Hersteller von medizinischen ...
    (Date:7/21/2014)... McCord Research, Inc. was recently granted ... This patent describes a method for accelerating wound ... inventor, Dr. McCord, this method includes administering or ... composition of an effective amount of hydroxytyrosol and ... such that the administration of the combination reduces ...
    Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2
    ... well-tolerated with signs of durable,disease control in advanced ... /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented preliminary results ... trial (DC-MEL-202). The,results showed that UVIDEM was well ... response in patients with,progressive metastatic melanoma. , The ...
    ... trial presented at ENDO 2007 , ,- Regulatory approvals ... recruitment in Europe , ,MONTREAL, QUEBEC -- (MARKET WIRE) ... that 26-week data from,its first Phase 3 study testing ... ENDO, the 89th,annual meeting of the Endocrine Society. The ...
    Cached Medicine Technology:IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
    (Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
    (Date:7/22/2014)... The park is the heart of a community. ... made a recent investment in outdoor recreation and ... playground equipment from American Parks Company™. , The community ... is a 475-unit community that was established in the ... a tropical paradise with lush shade trees, green-edged walking ...
    (Date:7/22/2014)... of the largest studies ever conducted into the genetic ... sites on chromosomes that harbor inherited genes tied to ... of researchers, now bring the total number of common ... Although these schizophrenia-associated genes aren,t specific enough to ... or will not develop the illness, researchers say they ...
    (Date:7/22/2014)... school lacrosse players are facing an increasing number of ... study finds. Although the most common injuries are ... researchers report. They note a better understanding of why ... to protect student athletes. "Concern over concussions in ... learn more about these injuries," said study co-author Dawn ...
    (Date:7/22/2014)... CarePoint Health is pleased to announce that Dr. ... the medical staff at Bayonne Medical Center. The election marks ... voted on by the physicians on staff. The office of ... to the administration at Bayonne Medical Center. Dr. Levine is ... to make the Medical Center the best it can be ...
    Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2
    ... Medical Innovations, Inc. (Amex: IMA ), a ... solutions, announced today that it will attend the upcoming ... 15, 2009 at the Westin St. Francis Hotel in ... Jon Russell, Vice President, Finance, will attend. Mr. ...
    ... Corporation (Nasdaq: BPUR ) announced today that ... stating that NASDAQ has again suspended enforcement of its ... listing, thereby extending the Company,s time in which to ... to resume on Monday, April 20, 2009. The Company ...
    ... Executive with Proven Ability to Develop Companies into ... Growth OpportunitiesFORT LAUDERDALE, Fla., Dec. 30 eDiets.com, ... provider of convenient at-home diet, fitness and healthy ... the company,s new President and CEO, effective immediately. ...
    ... didn,t halt women,s risk of developing disease , , TUESDAY, ... the supposed cancer-fighting powers of vitamins C and E, ... don,t prevent the disease in women. , And another ... new study found. , , "Simply taking antioxidant supplements ...
    ... had cancer as well as idiopathic pulmonary fibrosis, study finds ... in a gene previously found to help protect the lungs ... some inherited cases of a lethal lung disease affecting older ... the SFTPA2 gene have been found in families ...
    ... of adults and 19 percent of children taking chemotherapy drugs ... dose or experienced other mistakes involving their medications, according to ... professor of pediatrics at the University of Massachusetts Medical School, ... Journal of Clinical Oncology . , "As cancer care ...
    Cached Medicine News:Health News:Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009 2Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 3Health News:Vitamins Fail to Prevent Cancer: Study 2Health News:Vitamins Fail to Prevent Cancer: Study 3Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:Errors involving medications common in outpatient cancer treatment 2
    ... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
    ... Halogen HPX Streak Retinoscope ... handle and provides 40% ... conventional scopes and maintains ... which greatly enhances illumination ...
    Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
    3.5v Halogen HPX Spot Retinoscope provides 40% more light output than conventional scopes and maintains a consistent output level which greatly enhances illumination and produces the sharpest retina...
    Medicine Products: